<?xml version="1.0" encoding="UTF-8"?>



<records>

  <record>
    <language>eng</language>
          <publisher>Oriental Scientific Publishing Company</publisher>
        <journalTitle>Biomedical and Pharmacology Journal</journalTitle>
          <issn>0974-6242</issn>
            <publicationDate>2026-11-16</publicationDate>
    
        <volume>19</volume>
        <issue>4</issue>

 
    <startPage></startPage>
    <endPage></endPage>

	    <publisherRecordId>74243</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">In Silico Structure-Based Screening and Molecular Dynamics Evaluation of Cyclopeptide Candidates Targeting α-Synuclein Aggregation in Parkinson’s Disease</title>

    <authors>
	 


      <author>
       <name>Hatoon A. Niyazi</name>

 
		
	<affiliationId>1</affiliationId>
      </author>
    

	 


      <author>
       <name>Ala A. Azhari</name>


		
	<affiliationId>2</affiliationId>

      </author>
    

	 


      <author>
       <name>Hisham  N Altayb</name>

		
	<affiliationId>3</affiliationId>
      </author>
    

	 


      <author>
       <name>Turki M. Alharthi</name>

		
	<affiliationId>4</affiliationId>
      </author>
    


	 


      <author>
       <name>Wafaa Alhazmi</name>

		
	<affiliationId>5</affiliationId>
      </author>
    


	 


      <author>
       <name>Ahmad M. Alzahrani</name>

		
	<affiliationId>6</affiliationId>
      </author>
    
    </authors>
    
	    <affiliationsList>
	    
		
		<affiliationName affiliationId="1">Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.</affiliationName>
    

		
		<affiliationName affiliationId="2">Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</affiliationName>
    
		
		<affiliationName affiliationId="3">Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.</affiliationName>
    
		
		<affiliationName affiliationId="4">Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia</affiliationName>
    
		
		<affiliationName affiliationId="5">Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.</affiliationName>
    
		
		<affiliationName affiliationId="6">Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.</affiliationName>
    
	  </affiliationsList>






    <abstract language="eng">Parkinson’s disease (PD) is a neurodegenerative disorder linked to α-synuclein (α-syn) misfolding and aggregation. Targeting α-syn aggregation-prone regions is a promising therapeutic strategy. Here, an integrated in silico pipeline identified peptide inhibitors targeting these regions. AGGRESCAN3D identified key hotspots in the N-terminal segment and NAC domain. Screening peptides from the Cyclopeptide Database for physicochemical stability, solubility, and hemolytic potential yielded four candidates. Molecular docking identified GRCSVVYGLRCFPD as the top candidate (docking score: −196.33 kcal/mol), showing stable interactions with key residues (Val37, Tyr39, Thr44). Comparative 300 ns molecular dynamics simulations demonstrated that peptide binding reduced conformational fluctuations, increased structural compactness, and decreased solvent exposure of aggregation-prone regions. Steered molecular dynamics showed substantial mechanical unbinding resistance. MM-GBSA calculations confirmed favorable binding free energy (ΔG_TOTAL = −55.04 kcal/mol} , primarily driven by electrostatic and van der Waals interactions, with Arg10, Phe12, and Cys11 as key stabilization contributors. Principal component analysis and free energy landscape mapping confirmed stable low-energy conformational states. Overall, GRCSVVYGLRCFPD was identified as a top candidate exhibiting strong binding energy and mechanical resistance at α-synuclein aggregation hotspots. While these computational findings establish a prioritized peptide lead, subsequent in vitro experimental assays—including Thioflavin T (ThT) fluorescence kinetics, Transmission Electron Microscopy (TEM) imaging, and cell-based models—are necessary to experimentally confirm the inhibition of α-synuclein aggregation.</abstract>

    <fullTextUrl format="html">https://biomedpharmajournal.org/vol19no4/in-silico-structure-based-screening-and-molecular-dynamics-evaluation-of-cyclopeptide-candidates-targeting-%ce%b1-synuclein-aggregation-in-parkinsons-disease/</fullTextUrl>

<keywords language="eng">

      
        <keyword>In-silico drug discovery</keyword>
      

      
        <keyword> MDS</keyword>
      

      
        <keyword> Parkinson’s disease (PD)</keyword>
      

      
        <keyword> α-Synuclein aggregation</keyword>
      

      
        <keyword> Peptide Inhibitors</keyword>
      
</keywords>
  </record>
</records>